



Does bariatric surgery influence plasma levels of fetuin-A and leukocyte cell-derived chemotaxin-2 in patients with type 2 diabetes mellitus?

Hsien-Hao Huang^{1,2,*}, Chun Yeh^{3,4,*}, Jung-Chien Chen⁵, Tzong-Hsi Lee^{6,7}, Shu-Chun Chen^{8,9}, Wei-Jei Lee^{5,9} and Chih-Yen Chen^{10,11,12,13,14}

¹ Department of Emergency Medicine, Taipei Veterans General Hospital, Taipei, Taiwan

² Institute of Emergency and Critical Medicine, National Yang-Ming University School of Medicine, Taipei, Taiwan

³ Division of Gastroenterology, Department of Internal Medicine, Cheng-Hsin General Hospital, Taipei, Taiwan

⁴ Department of Internal Medicine, National Defense Medical Center, Taipei, Taiwan

⁵ Department of Surgery, Min-Sheng General Hospital, Taoyuan, Taiwan

⁶ Division of Gastroenterology and Hepatology, Department of Internal Medicine, Far Eastern Memorial Hospital, New Taipei City, Taiwan

⁷ Department of Nursing, Oriental Institute of Technology, New Taipei, Taiwan

⁸ Department of Nursing, Min-Sheng General Hospital, Taoyuan, Taiwan

⁹ Taiwan Society for Metabolic and Bariatric Surgery, Taoyuan, Taiwan

¹⁰ Division of Gastroenterology and Hepatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan

¹¹ Bariatric and Metabolic Surgery Center, Taipei Veterans General Hospital, Taipei, Taiwan

¹² Faculty of Medicine, National Yang-Ming University School of Medicine, Taipei, Taiwan

¹³ Taiwan Association for the Study of Small Intestinal Diseases, Guishan, Taiwan

¹⁴ Chinese Taipei Society for the Study of Obesity, Taipei, Taiwan

* These authors contributed equally to this work.

Submitted 22 February 2018

Accepted 11 May 2018

Published 12 June 2018

Corresponding authors

Tzong-Hsi Lee,
thleekimo@yahoo.com.tw
Chih-Yen Chen,
chency30@ms6.hinet.net,
chency@vghtpe.gov.tw

Academic editor

Daniela Foti

Additional Information and
Declarations can be found on
page 11

DOI 10.7717/peerj.4884

© Copyright
2018 Huang et al.

Distributed under
Creative Commons CC-BY 4.0

ABSTRACT

Background. Fetuin-A and leukocyte cell-derived chemotaxin-2 (LECT-2) are liver-derived proteins. Fetuin-A is an independent risk factor for type 2 diabetes (T2D) and obese patients with T2D have higher plasma fetuin-A levels than those without T2D. LECT-2 has positive correlation with the severity of both obesity and insulin resistance. The changes in plasma fetuin-A are not consistent after bariatric surgery and no studies have investigated the changes in LECT-2 on the obese patients with T2D after bariatric surgery.

Methods. Overall, 18 patients undergoing gastric bypass (GB) and 16 patients undergoing sleeve gastrectomy (SG) were enrolled. The fasting plasma fetuin-A and LECT-2 levels were measured at baseline, one week, three months, and one year after surgery.

Results. Both the GB and SG groups significantly decreased the body mass index (BMI), waist-to-hip ratio, a body shape index; the triglyceride, fasting blood sugar (FBS), hemoglobin A1c, C-peptide levels; and homeostatic model assessment (HOMA-IR) one year after surgery. The SG group showed a decreasing trend in plasma fetuin-A levels one year after SG surgery. There are no significant changes in LECT-2 one year after either GB or SG. Fetuin-A had a near significant negative relationship with insulin ($P = 0.056$) and HOMA-IR ($P = 0.050$) in the SG group. Changes in fetuin-A had a

OPEN ACCESS

significant positive relationship with changes in BMI ($P = 0.031$) and waist-to-hip ratio ($P = 0.031$) in the GB group and had a near significant positive correlation with FBS ($P = 0.051$) in the SG group.

Discussion. Neither GB nor SG modifies plasma levels of plasma fetuin-A or LECT-2 in T2D patients after surgery. The changes in plasma fetuin-A have a positive correlation with those of the BMI and waist-to-hip ratio 12 months after GB.

Subjects Gastroenterology and Hepatology, Nutrition, Surgery and Surgical Specialties, Metabolic Sciences

Keywords Fetuin-A, Bariatric surgery, Type 2 diabetes mellitus, Leukocyte cell-derived chemotaxin-2, Obesity, Sleeve gastrectomy, Gastric bypass

INTRODUCTION

The incidence of obesity has tripled over the past 20 years (*Hossain, Kavar & El Nahas, 2007*). With this increasing prevalence of obesity, diabetes has also increased at the same rate as 90% of diabetes is attributed to excess weight (*Hossain, Kavar & El Nahas, 2007*). Obesity and type 2 diabetes (T2D), sometimes together called diabetes, have thus become a worldwide public health problem and financial burden (*Ogurtsova et al., 2017; Chen et al., 2016; Ting et al., 2016*). Metabolic liver disease has also been reported in 30 to 67% of obese patients (*Luyckx et al., 1998; Blackburn & Mun, 2004*). The European Association for the Study of the Liver, the European Association for the Study of Diabetes, the European Association for the Study of Obesity have established clinical practice guidelines for the management of non-alcoholic fatty liver disease (*European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD) & European Association for the Study of Obesity (EASO), 2016*). Bariatric surgery is known to be the most effective treatment for obesity and can keep the promising long-term body weight loss in patients with morbid obesity (*Higa et al., 2011; Sjöström et al., 2009; Sjöström et al., 2007; Syu, Inui & Chen, 2017*). After 10 years, weight loss of 14 to 25% was maintained, depending on the type of bariatric surgery (*Sjöström et al., 2007*), and a mean excess weight loss of up to 57% was observed for gastric bypass (GB) surgery (*Higa et al., 2011*). A recent randomized trial has demonstrated that metabolic surgery, including gastric bypass and sleeve gastrectomy (SG), is as effective as surgical treatment in Asian patients who are non-morbidly obese (body mass index [BMI] $< 35 \text{ kg/m}^2$) with poorly-controlled T2D at one and two years after surgery (*Lee et al., 2011a; Chen et al., 2013*). Bariatric surgery (GB and SG) is known as the most effective and consistent method to improve metabolic syndrome, and has helped maintain body weight, glycemic control, and quality of life, when compared to medical therapy alone (*Schauer et al., 2014*). Moreover, both GB and SG had positive effects on metabolic liver disease (*Mattar et al., 2005; Klein et al., 2006; Billeter et al., 2016*).

Fetuin-A is a liver-derived protein and acts as an endogenous inhibitor of the insulin receptor tyrosine kinase (*Mathews et al., 2000*) in liver and skeletal muscle (*Auberger et al., 1989*). High levels of circulating fetuin-A are associated with insulin resistance (IR)

(Mori *et al.*, 2006; Stefan *et al.*, 2006; Reinehr & Roth, 2008; Ali, Nassif & Abdelaziz, 2016), and a higher fetuin-A level is associated with a higher risk of diabetes (Aroner *et al.*, 2017). Furthermore, fetuin-A is also an independent risk factor for T2D (Stefan *et al.*, 2008). Obese patients with T2D have higher fetuin-A than non-T2D patients before bariatric surgery (Yang *et al.*, 2015). Fetuin-A is positively correlated with metabolic liver disease and non-alcoholic fatty liver disease (Nascimbeni *et al.*, 2018). Thus, fetuin-A levels are correlated with IR, obese T2D, and metabolic liver disease. After bariatric surgery, the changes in fetuin-A levels are not consistent and can either decrease (Brix *et al.*, 2010; Jüllig *et al.*, 2014; Yang *et al.*, 2015) or remain unaffected (Kahraman *et al.*, 2013; Verras *et al.*, 2017). These discordant observations need further investigation.

Leukocyte cell-derived chemotaxin-2 (LECT-2) is a signaling molecule primarily expressed by hepatocytes (Yamagoe *et al.*, 1997; Yamagoe, Mizuno & Suzuki, 1998) and regulates hepatic β -catenin (Ovejero *et al.*, 2004) through Wnt/ β -catenin pathways implicated in hepatic metabolism (Liu *et al.*, 2011). Serum LECT-2 levels are increased in patients with obesity and fatty liver disease (Okumura *et al.*, 2013; Yoo *et al.*, 2017), suggesting that LECT-2 is a novel obesity-related protein (Okumura *et al.*, 2013). Circulating LECT-2 levels positively correlate with the severity of both obesity and IR (Lan *et al.*, 2014). However, there is few data available in the literature to explore changes in LECT-2 levels in obese patients with T2D after bariatric surgery.

In this study, our aim was to investigate the changes in fetuin-A and LECT-2 levels following bariatric surgery (GB and SG) and to correlate these alterations with other clinical parameters.

METHODS

Patients and metabolic surgery

A hospital-based design was adopted in the present study. Patients with T2D who received either laparoscopic mini-gastric bypass (GB) or SG were enrolled into the present study. Briefly, patients were eligible for either surgical procedure according to the following-diagnostic and inclusive criteria: (1) T2D onset of more than 6 months with hemoglobin A1c (HbA1c) $\geq 8\%$, under the intensive medical care of an endocrinologist; (2) BMI ≥ 25 kg/m² and ≤ 40 kg/m²; (3) willing to receive accessory therapy with diet control and exercise; (4) willing to undergo follow-up, and (5) willing to provide written informed consent.

Candidates were excluded if they (1) had cancer within 5 years of the study start; (2) were HIV-positive or had active pulmonary tuberculosis; (3) had cardiovascular diseases or cardiovascular instability within 6 months of study start; (4) had a history pulmonary embolism or uncontrolled coagulative diseases; (5) had serum creatinine levels >2 mg/dL, total bilirubin >2 mg/dL, prothrombin time prolonged >2 s, α -fetoprotein >20 ng/mL; (6) admitted to have chronic hepatitis B, C, liver cirrhosis, or inflammatory bowel diseases; (7) had acromegaly or receiving other organ transplantation; (8) underwent bariatric surgery, gastrointestinal surgery other than cholecystectomy, or had a prior abdominal septicemia; (9) had a history of alcohol or drug abuse, psychiatric diseases; or (10) presented uncooperative conditions.

Overall, 18 patients undergoing laparoscopic GB and an additional 16 patients undergoing laparoscopic SG were enrolled in this prospective, longitudinal study. The treatment decision was based on the predictors of diabetes remission after GB and SG, by using the Age, BMI, C-peptide, Duration of T2M (ABCD) score ([Lee et al., 2013](#); [Lee et al., 2015](#)). SG was recommended for T2D patients with an ABCD score >4; thus, bariatric surgery with SG was recommended for T2D patients with younger age, high BMI, high C-peptide levels and short duration of T2D ([Lee et al., 2015](#)).

This study was conducted at the Department of Surgery of the Min-Sheng General Hospital and at the Taipei Veterans General Hospital, and was approved by the Ethics Committee of each hospital (approval number: MSIRB2015020).

Surgical technique

GB was performed as described in our previous studies ([Lee et al., 2011a](#); [Lee et al., 2011b](#)). In brief, we used a standard 5-port laparoscopic technique to create a long-sleeve gastric tube using the EndoGIA stapler (Tyco, US Surgical, Norwalk, CT, USA). The gastric tube was approximately 2.0 cm wide along with lesser curvature from the antrum to the angle of His. We also used an EndoGIA stapler to create a Billroth II type loop gastroenterostomy with the small bowel about 120 cm distal to the ligament of Treitz. There was no drain tube left in place. Using the mesh plug technique with bio-absorbable hemostatic gauze (Cellulostat, Horng Tzer Medical Instruments, Kaohsiung, Taiwan) ([Chiu et al., 2006](#)), we closed all the trocar wounds. GB is categorized as malabsorptive metabolic surgery that bypasses the foregut (especially the duodenum), and can achieve good T2D remission and weight loss ([Lee et al., 2013](#)). GB improves metabolic syndrome and metabolic hepatic disease ([Mattar et al., 2005](#); [Klein et al., 2006](#)).

For SG, we used a laparoscopic stapler (EndoGIA; Covidien, Norwalk, CT, USA) with 60-cm cartridges (a 3.5-mm stapler height, blue load) to resect the greater curvature from the distal antrum (4 cm proximal to the pylorus) to the angle of His, including the complete fundus ([Lee et al., 2011b](#)). We left the remnant stomach tube, which was approximately 2 cm wide along the less curved side. The extended periumbilical trocar site was used for the extraction of the resected stomach portion. SG is volume restrictive metabolic surgery and also plays a role in T2D remission and weight loss ([Lee et al., 2015](#)). SG also has a good effect on metabolic hepatic disease ([Billeter et al., 2016](#)).

Study protocol and anthropometric measurement

Two separate occasions of follow-up: at baseline (before surgery), as well as 12 months post-operatively, were performed for all participants. Routine laboratory tests, including serum total cholesterol (TC), triglyceride (TG), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), fasting blood sugar (FBS), HbA1c, and C-peptide, as well as anthropometric measurements were performed on each study day. The homeostatic model assessment (HOMA-IR) index, calculated according to the formula $\text{plasma glucose (mmol/L)} \times \text{insulin } (\mu\text{U/mL}) / 22.5$, was measured and assessed IR ([Lee et al., 2011a](#); [Lee et al., 2011b](#)). A body shape index (ABSI) was based on the waist circumference adjusted for height and weight ([Krakauer & Krakauer, 2012](#)).

In addition, four separate follow-up visits (at baseline before surgery, as well as at one week, three and 12 months post-operatively), were organized for all participants. Routine laboratory tests, including plasma fetuin-A and LECT-2 levels, were performed on each study day.

Assays of plasma hepatokines levels

Venous blood samples were collected from the antecubital vein between 8 and 10 a.m. after an overnight fast before surgery, as well as at one week, three and 12 months after surgery. Blood samples were immediately transferred to a tube containing aprotinin (500 units/mL) (Lee *et al.*, 2011a). After centrifugation at $300 \times g$, plasma was separated, dispensed into polypropylene tubes in aliquots, and stored at -20°C until analysis. Enzyme immuno-assays for plasma fetuin-A (R&D Systems, Minneapolis, MN, USA) and LECT-2 (Medical & Biological Laboratories CO., LTD., Nagoya, Japan), were carried out in a single batch run and in a blinded fashion, as described in our previous study (Lee *et al.*, 2011a).

Statistical analysis

All statistical analyses were performed using the Statistical Package for Social Sciences, version 12.01 (SPSS, Inc., Chicago, Illinois). Continuous variables were expressed as the mean $\pm$ standard deviation (SD). The chi-square test or Fisher's exact test was used to compare categorical variables, while the Mann-Whitney *U* test was used to compare continuous variables. The Wilcoxon signed-rank test was used to compare baseline and post-operative variables. Friedman's one-way analysis of variance followed by a *post hoc* test was used to analyze the differences among plasma levels of fetuin-A and LECT-2 before surgery, as well as one week, three and 12 months after surgery. Correlations between the two groups were examined using Spearman's correlation analysis. A *P* value less than 0.05 was considered statistically significant.

RESULTS

Treatment effect one year after bariatric surgery

The flow chart of enrollment is shown in Fig. 1. In total, 18 patients (age: 42.8 ± 8.3 years, three males and 15 females) undergoing GB and 16 patients (age: 38.6 ± 9.2 years, 11 males and five females) undergoing SG were enrolled (Table 1). DM duration in the GB and SG groups was 4.0 ± 2.7 and 2.9 ± 3.0 years. Both the GB and SG groups significantly decreased the BMI, waist-to-hip ratio, ABSI, TG levels, FBS levels, HbA1c levels, C-peptide levels, and HOMA-IR one year after surgery (M12), as compared to before surgery measurements (M0).

Before surgery (M0), the SG group had significant higher a BMI ($P < 0.01$), lower ABSI ($P < 0.05$) and higher C-peptide levels ($P < 0.01$). One year after surgery (M12), the SG group had significant lower FBS ($P < 0.05$) and a higher C-peptide ($P < 0.01$) compared to the GB group.




Figure 1 Flow chart of the patient selection process.

Full-size [DOI: 10.7717/peerj.4884/fig-1](https://doi.org/10.7717/peerj.4884/fig-1)




Figure 2 The serum concentration of fetuin-A in gastric bypass (A; $n = 18$) and sleeve gastrectomy (B; $n = 16$) patients before (M0), 1 week (W1), 3 months (M3), and 1 year (M12) after surgery.

Full-size [DOI: 10.7717/peerj.4884/fig-2](https://doi.org/10.7717/peerj.4884/fig-2)

The changes in fetuin-A and LECT-2 levels one year after GB and SG surgery

One year after SG surgery, GB group had no significant changes in fetuin-A ($P > 0.05$; Fig. 2A). Fetuin-A levels showed a decreasing trend ($P = 0.072$; Fig. 2B). There were no significant changes in LECT-2 at W1, M3 and M12 after GB or SG surgery ($P > 0.05$; Fig. 3).




Figure 3 The serum concentration of leukocyte cell-derived chemotaxin-2 in gastric bypass (A; $n = 18$) and sleeve gastrectomy (B; $n = 16$) patients before (M0), 1 week (W1), 3 months (M3), and 1 year (M12) after surgery.

Full-size [DOI: 10.7717/peerj.4884/fig-3](https://doi.org/10.7717/peerj.4884/fig-3)

Table 1 Characteristics of GB and SG patients before surgery (M0) and 1 year after surgery (M12).

	GB ($n = 18$)		SG ($n = 16$)	
	M0	M12	M0	M12
BMI (kg/m^2)	30.700 ± 3.600	$25.100 \pm 2.200^{***}$	$36.300 \pm 5.600^{**}$	$27.300 \pm 4.600^{***}$
Waist-to-hip ratio	0.950 ± 0.048	$0.869 \pm 0.048^{***}$	0.959 ± 0.076	$0.842 \pm 0.076^{***}$
ABSI	0.082 ± 0.005	$0.076 \pm 0.004^{***}$	$0.078 \pm 0.005^*$	$0.074 \pm 0.006^{\#}$
TC (mg/dL)	194.875 ± 45.716	$166.875 \pm 23.827^{\#}$	193.286 ± 42.134	178.143 ± 29.501
TG (mg/dL)	202.000 ± 130.853	$102.875 \pm 52.262^{***}$	255.857 ± 155.109	$97.286 \pm 30.883^{\#}$
HDL-C (mg/dL)	43.000 ± 7.510	45.375 ± 8.180	37.583 ± 7.204	$49.000 \pm 9.658^{\#}$
LDL-C (mg/dL)	123.625 ± 32.114	107.125 ± 20.340	119.000 ± 33.059	111.929 ± 26.439
FBS (mg/dL)	165.412 ± 48.647	$109.176 \pm 33.787^{***}$	148.071 ± 59.285	$90.500 \pm 16.080^{**}$
HbA1c (%)	9.141 ± 1.450	$6.353 \pm 0.873^{***}$	8.350 ± 1.794	$5.864 \pm 0.438^{***}$
Insulin ($\mu\text{U/mL}$)	18.158 ± 28.806	4.409 ± 3.327	13.155 ± 7.366	$4.582 \pm 2.679^{***}$
C-peptide (ng/mL)	2.562 ± 0.996	$1.319 \pm 0.560^{***}$	$3.786 \pm 1.521^{**}$	$1.955 \pm 0.496^{**}$
HOMA-IR	6.647 ± 8.740	$1.247 \pm 1.125^{\#}$	5.253 ± 4.247	$0.974 \pm 0.498^{**}$

Notes.
 Abbreviations: GB, gastric bypass; SG, sleeve gastrectomy; MO, before surgery; M12, months after surgery; BMI, body mass index; ABSI, a body shape index; TC, total cholesterol; TG, triglyceride; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; FBS, fasting blood sugar; HOMA-IR, homeostatic model assessment index insulin resistance.
 Asterisks indicates statistical difference between gastric bypass and sleeve gastrectomy groups:
 $^*P < 0.05$.
 $^{**}P < 0.01$.
 $^{\#}$ indicates statistical difference between groups compared before and after surgery:
 $^{\#}P < 0.05$.
 $^{##}P < 0.01$.
 $^{***}P < 0.001$.

We pooled these data (GB+SG = 34 cases), but did not detect any significant changes in fetuin-A ($1,094.1 \pm 852.0$, 686.7 ± 508.5 , 734.4 ± 459.4 vs. $1,254.7 \pm 1,202.3$ $\mu\text{g/mL}$) and LECT-2 (0.17 ± 0.09 , 0.20 ± 0.06 , 0.15 ± 0.09 vs. 0.16 ± 0.12 ng/mL) after bariatric surgery.

Table 2 Relationships between either fetuin-A or leukocyte cell-derived chemotaxin-2 levels and various parameters at baseline before surgery.

	GB (<i>n</i> = 18)				SG (<i>n</i> = 16)			
	Fetuin-A (μg/mL)		LECT-2 (ng/mL)		Fetuin-A (μg/mL)		LECT-2 (ng/mL)	
	rho	<i>P</i>	rho	<i>P</i>	rho	<i>P</i>	rho	<i>P</i>
BW (kg)	−0.107	0.662	0.014	0.954	−0.332	0.202	−0.0676	0.797
BMI (kg/m ²)	0.027	0.908	−0.006	0.980	−0.335	0.198	−0.015	0.952
Waist-to-hip ratio	0.089	0.717	0.014	0.954	−0.081	0.754	0.056	0.831
ABSI	0.141	0.569	0.030	0.902	−0.032	0.900	−0.118	0.656
TC (mg/dL)	−0.265	0.281	−0.277	0.259	−0.471	0.073	0.357	0.185
TG (mg/dL)	−0.282	0.252	0.016	0.948	−0.343	0.186	0.205	0.436
HDL-C (mg/dL)	0.215	0.383	−0.348	0.153	0.100	0.705	0.239	0.366
LDL-C (mg/dL)	−0.136	0.580	−0.221	0.369	−0.074	0.780	0.347	0.182
FBS (mg/dL)	−0.145	0.558	0.239	0.334	−0.322	0.215	0.409	0.112
HbA1c (%)	0.056	0.818	0.096	0.699	−0.232	0.378	0.118	0.656
Insulin (μU/mL)	0.158	0.524	0.212	0.392	−0.500	0.056	0.200	0.465
C-peptide (ng/mL)	−0.267	0.278	0.146	0.558	0.221	0.403	0.185	0.483
HOMA-IR	0.129	0.603	0.290	0.238	−0.494	0.050	0.279	0.287

Notes. Abbreviations: GB, gastric bypass; SG, sleeve gastrectomy; BMI, body mass index; ABSI, a body shape index; TC, total cholesterol; TG, triglyceride; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; FBS, fasting blood sugar; HOMA-IR, homeostatic model assessment index insulin resistance.

Relationships between fetuin-A or LECT-2 and clinical parameters before surgery (M0) and one year after surgery (M12)

Before surgery (M0), fetuin-A showed no significant relationships with different parameters in the GB group (Table 2). Fetuin-A had a near significant negative relationship with insulin levels ($P = 0.056$) and the HOMA-IR index ($P = 0.050$) in the SG group. LECT-2 had no significant relationship with parameters in either the GB or SG group.

One year after surgery (M12), fetuin-A had a significant, positive relationship with HbA1c ($P = 0.033$) in the GB group (Table 3) and showed only a trend for a negative relationship with TC ($P = 0.087$) in the SG group.

The relationships between change (Δ) in fetuin-A or LECT-2 and changes in various parameters one year after surgery (M12)

In Table 4, Δ fetuin-A exhibited a significant, positive relationship with Δ BMI ($P = 0.031$) and Δ waist-to-hip ratio ($P = 0.031$) in the GB group, and had a near significant positive correlation with Δ FBS ($P = 0.051$) in the SG group. However, Δ LECT-2 did not reveal significant correlation with any parameters in either GB or SG groups.

DISCUSSION

Our current study demonstrated that the BMI, waist-to-hip ratio, ABSI, TG levels, FBS levels, HbA1c levels, C-peptide levels, and HOMA-IR index were significantly decreased one year after either GB or SG, supporting the important role of bariatric surgery in maintaining long-term weight loss and improving glycemic control (Chen et al., 2013; Schauer et al., 2014; Yeh et al., 2017). However, neither GB nor SG showed any temporal

Table 3 Relationships between either fetuin-A or leukocyte cell-derived chemotaxin-2 levels and various parameters 12 months after surgery.

	GB (<i>n</i> = 18)				SG (<i>n</i> = 16)			
	Fetuin-A (μg/mL)		LECT-2 (ng/mL)		Fetuin-A (μg/mL)		LECT-2 (ng/mL)	
	rho	<i>P</i>	rho	<i>P</i>	rho	<i>P</i>	rho	<i>P</i>
BW (kg)	−0.256	0.312	−0.319	0.207	−0.020	0.94	−0.090	0.750
BMI (kg/m ²)	−0.407	0.143	−0.271	0.340	−0.081	0.773	0.042	0.880
Waist-to-hip ratio	0.018	0.943	−0.422	0.099	0.358	0.221	−0.270	0.362
ABSI	0.385	0.167	−0.105	0.594	−0.104	0.723	−0.115	0.696
TC (mg/dL)	−0.152	0.563	−0.383	0.139	−0.470	0.087	−0.046	0.868
TG (mg/dL)	0.247	0.348	−0.395	0.127	−0.213	0.543	0.020	0.940
HDL-C (mg/dL)	−0.319	0.224	−0.140	0.594	−0.028	0.921	−0.118	0.682
LDL-C (mg/dL)	−0.009	0.969	−0.330	0.207	−0.420	0.129	0.020	0.940
FBS (mg/dL)	0.209	0.415	−0.424	0.087	−0.046	0.868	0.057	0.832
HbA1c (%)	0.517	0.033*	−0.319	0.207	0.222	0.435	−0.303	0.286
Insulin (μU/mL)	−0.368	0.156	−0.459	0.072	−0.300	0.304	0.045	0.878
C-peptide (ng/mL)	−0.403	0.118	−0.327	0.211	0.132	0.656	0.203	0.493
HOMA-IR	−0.265	0.314	−0.479	0.058	−0.368	0.206	0.005	0.978

Notes.
Abbreviations: GB, gastric bypass; SG, sleeve gastrectomy; BMI, body mass index; ABSI, a body shape index; TC, total cholesterol; TG, triglyceride; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; FBS, fasting blood sugar; HOMA-IR, homeostatic model assessment index insulin resistance.
**P* < 0.05.

Table 4 Relationships between changes in either fetuin-A or leukocyte cell-derived chemotaxin-2 levels and changes in various parameters 12 months after surgery.

	GB (<i>n</i> = 18)				SG (<i>n</i> = 16)			
	ΔFetuin-A (μg/mL)		ΔLECT-2 (ng/mL)		ΔFetuin-A (μg/mL)		ΔLECT-2 (ng/mL)	
	rho	<i>P</i>	rho	<i>P</i>	rho	<i>P</i>	rho	<i>P</i>
ΔBW (kg)	−0.320	0.203	0.0478	0.846	0.156	0.583	0.121	0.670
ΔBMI (kg/m ²)	0.574	0.031*	−0.323	0.251	−0.244	0.390	0.002	0.988
ΔWaist-to-hip ratio	0.538	0.031*	−0.094	0.721	0.360	0.214	0.006	0.978
ΔABSI	0.187	0.511	−0.125	0.659	−0.115	0.696	0.071	0.806
ΔTC (mg/dL)	−0.347	0.182	−0.078	0.763	−0.427	0.121	0.015	0.952
ΔTG (mg/dL)	−0.113	0.664	0.137	0.601	0.341	0.244	0.203	0.493
ΔHDL-C (mg/dL)	0.065	0.805	−0.123	0.640	0.257	0.382	−0.512	0.070
ΔLDL-C (mg/dL)	−0.227	0.390	−0.052	0.839	−0.411	0.138	−0.279	0.324
ΔFBS (mg/dL)	0.429	0.083	0.223	0.382	0.525	0.051	−0.046	0.868
ΔHbA1c (%)	0.228	0.371	0.404	0.104	0.266	0.348	−0.266	0.348
ΔInsulin (μU/mL)	0.139	0.601	−0.209	0.429	0.033	0.906	0.159	0.591
ΔC-peptide (ng/mL)	0.079	0.763	−0.044	0.865	−0.374	0.199	−0.451	0.116
ΔHOMA-IR	0.388	0.133	−0.050	0.848	0.214	0.469	0.050	0.863

Notes.
Abbreviations: GB, gastric bypass; SG, sleeve gastrectomy; MO, before surgery; M12, months after surgery; BMI, body mass index; ABSI, a body shape index; TC, total cholesterol; TG, triglyceride; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; FBS, fasting blood sugar; HOMA-IR, homeostatic model assessment index insulin resistance.
**P* < 0.05.

Table 5 Summary of the temporal effects on changes in fetuin-A after bariatric surgery.

Morbidly obese (first & correspondence author)	Type of surgery	Number	BMI	T2D (number)	NAFLD (number)	Fetuin-A (length of follow-up)
Kahraman & Canbay et al., 2013 Clinical Science.	GB	108	53.3		Yes (108)	Increased (4M), Decreased (6M)
Verras & Kiortsis et al., 2017 Hormones	SG	20	42.5			Decreased (6M)
Yang & Lee et al., 2015 Obesity Surgery	GB	108	41.9	Yes (32)		Decreased (12M)
	SG	22	43.0	Yes (11)		Decreased (12M)
Brix & Scherthaner et al., 2010 The Journal of Clinical Endocrinology and Metabolism	GB	75	45.9			Decreased (16M)
Jüllig & Murphy et al., 2014 PLOS ONE	GB	8	42.1	Yes (8)		Decreased (3D)
	SG	7	42.3	Yes (7)		Decreased (3D)
Our current data	GB	18	30.7	Yes (18)		No effect (7D, 3M, 12M)
	SG	16	36.3	Yes (16)		Trend of decrease (7D, 3M, 12M)

Notes.

Abbreviations: GB, gastric bypass; SG, sleeve gastrectomy; BMI, body mass index; T2D, Type 2 diabetes mellitus; NAFLD, non-alcohol fatty liver disease; D, days; M, months.

effects on plasma levels of fetuin-A and LECT-2 at the one-year follow-up. Only the GB group had a positive relationship between changes in fetuin-A levels, as well as those in the BMI and waist-to-hip ratio.

Significantly higher fetuin-A levels of up to 877 $\mu\text{g/mL}$ have been reported in the morbidly obese (Ix et al., 2008; Brix et al., 2010). In our study, the levels of fetuin-A were comparable with those of previous studies (Ix et al., 2008; Brix et al., 2010), supporting the concept that obesity is seemingly one of the major factors for increased fetuin-A. Diabetes is another important related factor for increased fetuin-A levels. Patients with newly diagnosed T2D and impaired glucose tolerance have been reported to have higher serum fetuin-A concentrations than normal subjects (Ou et al., 2011). T2D patients have been documented to have higher fetuin-A concentrations than controls (Stefan et al., 2008; Ou et al., 2011; Sun et al., 2013; Yang et al., 2015), and plasma fetuin-A is independently and positively associated with a higher risk of developing T2D (Ix et al., 2008; Stefan et al., 2008; Sun et al., 2013), even after adjustment for age (Stefan et al., 2008) or exclusion of non-alcohol fatty liver disease (Ou et al., 2011).

The literature is limited regarding the study of fetuin-A levels after bariatric surgery. In the obese, the concentration of fetuin-A has been shown to increase at four months (Kahraman et al., 2013), remain unchanged at six months (Kahraman et al., 2013), decrease at 12 months (Yang et al., 2015), or decrease at 16 months (Brix et al., 2010) in the morbidly obese after GB (Table 5). On the other hand, fetuin-A has also been showed to be either unchanged at 6 months (Verras et al., 2017) or decreased at 12 months (Yang et al., 2015) in the morbidly obese after SG. These results regarding fetuin-A levels after either GB or SG are very inconsistent. Diabetes, age, Caucasian origin, higher serum triglyceride levels, visceral adiposity, and nonalcoholic fatty liver disease are reported known related factors and require more investigation to control for potential confounding factors in the future

(*Ix et al., 2008; Stefan et al., 2008; Ou et al., 2011; Song et al., 2011; Haukeland et al., 2012; Sun et al., 2013; Stefan et al., 2014*).

To the best of our knowledge, this study is the first to investigate the detailed temporal effects of bariatric surgery on fetuin-A levels in the obese with T2D. Fetuin-A has ever been reported to show an early significant decrease in the morbidly obese (BMI about 42) with T2D, three days after GB and SG (*Jüllig et al., 2014*). In our study, lower BMI (36.5 and 30.7 in SG and GB, i.e., mainly non-morbidly obese) might be the factor responsible for the non-significant decrease in the fetuin-A curve after surgery.

Serum concentrations of fetuin-A have been reported to be positively correlated with BMI in diabetics (*Stefan et al., 2014*) and in the obese (*Erdmann et al., 2012; Ismail et al., 2012*). Our study is the first to show that changes in fetuin-A levels had a positive correlation with those in BMI after GB surgery. A causal association has previously been proposed regarding circulating levels of fetuin-A and BMI (*Thakkestian et al., 2014*).

Furthermore, fetuin-A has also been reported to be positive correlated with waist circumference (*Ismail et al., 2012*), while changes in fetuin-A have also shown to be positively correlated with waist circumference (*Reinehr & Roth, 2008*). In addition, fetuin-A levels were previously demonstrated to be positively correlated with waist-to-hip ratio one year after GB and SG (*Yang et al., 2015*). Our study is the first to reveal that changes in fetuin-A levels were positively correlated with those of waist-to-hip ratio one year after GB surgery. The changes in fetuin-A suggest re-evaluation as a therapeutic marker in obese patients with T2D after GB surgery.

To date, there is no information available regarding the influences of bariatric surgery on LECT-2. Our study showed LECT-2 levels did not change in obese patients with T2D after bariatric surgery. The possible use of LECT-2 as a therapeutic marker requires further investigation.

Our study had some limitations. First, the sample size was small. Second, a type-2 statistical error was due to the selected study subjects. Third, results of liver function testing, sonography, and liver histology were not available for all patients.

In summary, neither GB nor SG modifies plasma levels of plasma fetuin-A and LECT-2 in T2D patients after surgery. The changes in plasma fetuin-A show a positive correlation with changes in BMI and waist-to-hip ratio 12 months after GB.

ADDITIONAL INFORMATION AND DECLARATIONS

Funding

This work was supported by grants from the Min-Sheng General Hospital, Taoyuan and Taiwan Ministry of Science and Technology (MOST 104-2314-B-010-005-), as well as the Cheng Hsin General Hospital-National Yang-Ming University Joint Research Program (CY10517, CY10618 and CY10717 to Chun Yeh and Chih-Yen Chen); and Far Eastern Memorial Hospital-National Yang-Ming University Joint Research Program (105DN15, 106DN15 and 107DN14 to Tzong-Hsi Lee and Chih-Yen Chen), Taipei, Taiwan. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Grant Disclosures

The following grant information was disclosed by the authors:

Min-Sheng General Hospital, Taoyuan and Taiwan Ministry of Science and Technology: MOST 104-2314-B-010-005-.

Cheng Hsin General Hospital-National Yang-Ming University Joint Research Program: CY10517, CY10618, CY10717.

Far Eastern Memorial Hospital-National Yang-Ming University Joint Research Program: 105DN15, 106DN15, 107DN14.

Competing Interests

The authors declare there are no competing interests.

Author Contributions

- Hsien-Hao Huang and Chih-Yen Chen conceived and designed the experiments, performed the experiments, analyzed the data, contributed reagents/materials/analysis tools, prepared figures and/or tables, authored or reviewed drafts of the paper, approved the final draft.
- Chun Yeh and Tzong-Hsi Lee conceived and designed the experiments, approved the final draft.
- Jung-Chien Chen, Shu-Chun Chen and Wei-Jei Lee performed the experiments, approved the final draft.

Human Ethics

The following information was supplied relating to ethical approvals (i.e., approving body and any reference numbers):

Min-Sheng General Hospital and Taipei Veterans General Hospital approved this study (approval number MSIRB2015020).

Data Availability

The following information was supplied regarding data availability:

The raw data are provided in a [Supplemental File](#).

Supplemental Information

Supplemental information for this article can be found online at <http://dx.doi.org/10.7717/peerj.4884#supplemental-information>.

REFERENCES

- Ali SA, Nassif WM, Abdelaziz DH. 2016. Alterations in serum levels of fetuin A and selenoprotein P in chronic hepatitis C patients with concomitant type 2 diabetes: a case-control study. *Clinics And Research in Hepatology and Gastroenterology* 40(4):465–470 DOI [10.1016/j.clinre.2015.12.003](https://doi.org/10.1016/j.clinre.2015.12.003).
- Aroner SA, Mukamal KJ, St-Jules DE, Budoff MJ, Katz R, Criqui MH, Allison MA, De Boer IH, Siscovick DS, Ix JH, Jensen MK. 2017. Fetuin-A and risk of diabetes

- independent of liver fat content: the multi-ethnic study of atherosclerosis. *American Journal of Epidemiology* **185**(1):54–64 DOI [10.1093/aje/kww095](https://doi.org/10.1093/aje/kww095).
- Auberger P, Falquerho L, Contreres JO, Pages G, Le Cam G, Rossi B, Le Cam A. 1989.** Characterization of a natural inhibitor of the insulin receptor tyrosine kinase: cDNA cloning, purification, and anti-mitogenic activity. *Cell* **58**(4):631–640 DOI [10.1016/0092-8674\(89\)90098-6](https://doi.org/10.1016/0092-8674(89)90098-6).
- Billeter AT, Senft J, Gotthardt D, Knefeli P, Nickel F, Schulte T, Fischer L, Nawroth PP, Büchler MW, Müller-Stich BP. 2016.** Combined non-alcoholic fatty liver disease and Type 2 diabetes mellitus: sleeve gastrectomy or gastric bypass?—a controlled matched pair study of 34 patients. *Obesity Surgery* **26**(8):1867–1874 DOI [10.1007/s11695-015-2006-y](https://doi.org/10.1007/s11695-015-2006-y).
- Blackburn GL, Mun EC. 2004.** Effects of weight loss surgeries on liver disease. *Seminars in Liver Disease* **24**(4):371–379 DOI [10.1055/s-2004-860866](https://doi.org/10.1055/s-2004-860866).
- Brix JM, Stingl H, Höllerl F, Schernthaner GH, Kopp HP, Schernthaner G. 2010.** Elevated fetuin-A concentrations in morbid obesity decrease after dramatic weight loss. *The Journal of Clinical Endocrinology and Metabolism* **95**(11):4877–4881 DOI [10.1210/jc.2010-0148](https://doi.org/10.1210/jc.2010-0148).
- Chen CY, Lee WJ, Asakawa A, Fujitsuka N, Chong K, Chen SC, Lee SD, Inui A. 2013.** Insulin secretion and interleukin-1 β dependent mechanisms in human diabetes remission after metabolic surgery. *Current Medicinal Chemistry* **20**(18):2374–2388 DOI [10.2174/0929867311320180008](https://doi.org/10.2174/0929867311320180008).
- Chen YC, Inui A, Chang ES, Chen SC, Lee WJ, Chen CY. 2016.** Comparison of gut hormones and adipokines stimulated by glucagon test among patients with type II diabetes mellitus after metabolic surgery. *Neuropeptides* **55**:39–45 DOI [10.1016/j.npep.2015.11.002](https://doi.org/10.1016/j.npep.2015.11.002).
- Chiu CC, Lee WJ, Wang W, Wei PL, Huang MT. 2006.** Prevention of trocar-wound hernia in laparoscopic bariatric operations. *Obesity Surgery* **16**(7):913–918 DOI [10.1381/096089206777822269](https://doi.org/10.1381/096089206777822269).
- European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). 2016.** EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. *Diabetologia* **59**(6):1121–1140 DOI [10.1007/s00125-016-3902-y](https://doi.org/10.1007/s00125-016-3902-y).
- Erdmann J, Salmhofer H, Knauß A, Mayr M, Wagenpfeil S, Sypchenko O, Lupp P, Schusdziarra V. 2012.** Relationship of fetuin-A levels to weight-dependent insulin resistance and type 2 diabetes mellitus. *Regulatory Peptides* **178**(1–3):6–10 DOI [10.1016/j.regpep.2012.02.004](https://doi.org/10.1016/j.regpep.2012.02.004).
- Haukeland JW, Dahl TB, Yndestad A, Gladhaug IP, Løberg EM, Haaland T, Konopski Z, Wium C, Aasheim ET, Johansen OE, Aukrust P, Halvorsen B, Birkeland KI. 2012.** Fetuin A in nonalcoholic fatty liver disease: *in vivo* and *in vitro* studies. *European Journal of Endocrinology* **166**(3):503–510 DOI [10.1530/EJE-11-0864](https://doi.org/10.1530/EJE-11-0864).

- Higa K, Ho T, Tercero F, Yunus T, Boone KB. 2011. Laparoscopic Roux-en-Y gastric bypass: 10-year follow-up. *Surgery for Obesity and Related Diseases* 7(4):516–525 DOI 10.1016/j.soard.2010.10.019.
- Hossain P, Kavar B, El Nahas M. 2007. Obesity and diabetes in the developing world—a growing challenge. *The New England Journal of Medicine* 356(3):213–215 DOI 10.1056/NEJMp068177.
- Ismail NA, Ragab S, El Dayem SM, Elbaky AA, Salah N, Hamed M, Assal H, Koura H. 2012. Fetuin-A levels in obesity: differences in relation to metabolic syndrome and correlation with clinical and laboratory variables. *Archives of Medical Science* 8(5):826–833 DOI 10.5114/aoms.2012.31616.
- Ix JH, Wassel CL, Kanaya AM, Vittinghoff E, Johnson KC, Koster A, Cauley JA, Harris TB, Cummings SR, Shlipak MG, Health ABC Study. 2008. Fetuin-A and incident diabetes mellitus in older persons. *Journal of the American Medical Association* 300(2):182–188 DOI 10.1001/jama.300.2.182.
- Jüllig M, Yip S, Xu A, Smith G, Middleditch M, Booth M, Babor R, Beban G, Murphy R. 2014. Lower fetuin-A, retinol binding protein 4 and several metabolites after gastric bypass compared to sleeve gastrectomy in patients with type 2 diabetes. *Public Library of Science One* 9(5):e96489 DOI 10.1371/journal.pone.0096489.
- Kahraman A, Sowa JP, Schlattjan M, Sydor S, Pronadl M, Wree A, Beilfuss A, Kili-carслан A, Altinbaş A, Bechmann LP, Syn WK, Gerken G, Canbay A. 2013. Fetuin-A mRNA expression is elevated in NASH compared with NAFL patients. *Clinical Science* 125(8):391–400 DOI 10.1042/CS20120542.
- Klein S, Mittendorfer B, Eagon JC, Patterson B, Grant L, Feirt N, Seki E, Brenner D, Korenblat K, McCrea J. 2006. Gastric bypass surgery improves metabolic and hepatic abnormalities associated with nonalcoholic fatty liver disease. *Gastroenterology* 130(6):1564–1572 DOI 10.1053/j.gastro.2006.01.042.
- Krakauer NY, Krakauer JC. 2012. A new body shape index predicts mortality hazard independently of body mass index. *Public Library of Science One* 7(7):e39504 DOI 10.1371/journal.pone.0039504.
- Lan F, Misu H, Chikamoto K, Takayama H, Kikuchi A, Mohri K, Takata N, Hayashi H, Matsuzawa-Nagata N, Takeshita Y, Noda H, Matsumoto Y, Ota T, Nagano T, Nakagen M, Miyamoto K, Takatsuki K, Seo T, Iwayama K, Tokuyama K, Matsugo S, Tang H, Saito Y, Yamagoe S, Kaneko S, Takamura T. 2014. LECT2 functions as a hepatokine that links obesity to skeletal muscle insulin resistance. *Diabetes* 63(5):1649–1664 DOI 10.2337/db13-0728.
- Lee WJ, Almulaifi A, Tsou JJ, Ser KH, Lee YC, Chen SC. 2015. Laparoscopic sleeve gastrectomy for type 2 diabetes mellitus: predicting the success by ABCD score. *Surgery for Obesity and Related Diseases* 11(5):991–996 DOI 10.1016/j.soard.2014.12.027.
- Lee WJ, Chen CY, Chong K, Lee YC, Chen SC, Lee SD. 2011a. Changes in post-prandial gut hormones after metabolic surgery: a comparison of gastric bypass and sleeve gastrectomy. *Surgery for Obesity And Related Diseases* 7(6):683–690 DOI 10.1016/j.soard.2011.07.009.

- Lee WJ, Chong K, Ser KH, Lee YC, Chen SC, Chen JC, Tsai MH, Chuang LM. 2011b. Gastric bypass vs sleeve gastrectomy for type 2 diabetes mellitus: a randomized controlled trial. *Archives of Surgery* 146(2):143–148 DOI 10.1001/archsurg.2010.326.
- Lee WJ, Hur KY, Lakadawala M, Kasama K, Wong SK, Chen SC, Lee YC, Ser KH. 2013. Predicting success of metabolic surgery: age, body mass index, C-peptide, and duration score. *Surgery for Obesity and Related Diseases* 9(3):379–384 DOI 10.1016/j.soard.2012.07.015.
- Liu H, Fergusson MM, Wu JJ, Rovira II, Liu J, Gavrilova O, Lu T, Bao J, Han D, Sack MN, Finkel T. 2011. Wnt signaling regulates hepatic metabolism. *Science Signaling* 4(158):Article ra6 DOI 10.1126/scisignal.2001249.
- Luyckx FH, Desai C, Thiry A, Dewé W, Scheen AJ, Gielen JE, Lefèbvre PJ. 1998. Liver abnormalities in severely obese subjects: effect of drastic weight loss after gastroplasty. *International Journal of Obesity and Related Metabolic Disorders* 22(3):222–226 DOI 10.1038/sj.ijo.0800571.
- Mathews ST, Chellam N, Srinivas PR, Cintron VJ, Leon MA, Goustin AS, Grunberger G. 2000. Alpha2-HSG, a specific inhibitor of insulin receptor autophosphorylation, interacts with the insulin receptor. *Molecular and Cellular Endocrinology* 164(1–2):87–98 DOI 10.1016/S0303-7207(00)00237-9.
- Mattar SG, Velcu LM, Rabinovitz M, Demetris AJ, Krasinskas AM, Barinas-Mitchell E, Eid GM, Ramanathan R, Taylor DS, Schauer PR. 2005. Surgically-induced weight loss significantly improves nonalcoholic fatty liver disease and the metabolic syndrome. *Annals of Surgery* 242(4):610–617 DOI 10.1097/01.sla.0000179652.07502.3f.
- Mori K, Emoto M, Yokoyama H, Araki T, Teramura M, Koyama H, Shoji T, Inaba M, Nishizawa Y. 2006. Association of serum fetuin-A with insulin resistance in type 2 diabetic and nondiabetic subjects [Abstract 468]. *Diabetes Care* 29(2) DOI 10.2337/diacare.29.02.06.dc05-1484.
- Nascimbeni F, Romagnoli D, Ballestri S, Baldelli E, Lugari S, Sirotti V, Giampaoli V, Lonardo A. 2018. Do nonalcoholic fatty liver disease and fetuin-A play different roles in symptomatic coronary artery disease and peripheral arterial disease? *Diseases* 6(1):Article E17 DOI 10.3390/diseases6010017.
- Ogurtsova K, Da Rocha Fernandes JD, Huang Y, Linnenkamp U, Guariguata L, Cho NH, Cavan D, Shaw JE, Makaroff LE. 2017. IDF diabetes atlas: global estimates for the prevalence of diabetes for 2015 and 2040. *Diabetes Research and Clinical Practice* 128:40–50 DOI 10.1016/j.diabres.2017.03.024.
- Okumura A, Unoki-Kubota H, Matsushita Y, Shiga T, Moriyoshi Y, Yamagoe S, Kaburagi Y. 2013. Increased serum leukocyte cell-derived chemotaxin 2 (LECT2) levels in obesity and fatty liver. *Bioscience Trends* 7(6):276–283.
- Ou HY, Yang YC, Wu HT, Wu JS, Lu FH, Chang CJ. 2011. Serum fetuin-A concentrations are elevated in subjects with impaired glucose tolerance and newly diagnosed type 2 diabetes. *Clinical Endocrinology* 75(4):450–455 DOI 10.1111/j.1365-2265.2011.04070.x.
- Ovejero C, Cavard C, Périanin A, Hakvoort T, Vermeulen J, Godard C, Fabre M, Chafey P, Suzuki K, Romagnolo B, Yamagoe S, Perret C. 2004. Identification of

- the leukocyte cell-derived chemotaxin 2 as a direct target gene of beta-catenin in the liver. *Hepatology* **40**(1):167–176 DOI [10.1002/hep.20286](https://doi.org/10.1002/hep.20286).
- Reinehr T, Roth CL. 2008.** Fetuin-A and its relation to metabolic syndrome and fatty liver disease in obese children before and after weight loss. *The Journal of Clinical Endocrinology and Metabolism* **93**(11):4479–4485 DOI [10.1210/jc.2008-1505](https://doi.org/10.1210/jc.2008-1505).
- Schauer PR, Bhatt DL, Kirwan JP, Wolski K, Brethauer SA, Navaneethan SD, Aminian A, Pothier CE, Kim ES, Nissen SE, Kashyap SR, STAMPEDE Investigators. 2014.** Bariatric surgery versus intensive medical therapy for diabetes—3-year outcomes. *The New England Journal of Medicine* **370**(21):2002–2013 DOI [10.1056/NEJMoa1401329](https://doi.org/10.1056/NEJMoa1401329).
- Sjöström L, Gummesson A, Sjöström CD, Narbro K, Peltonen M, Wedel H, Bengtsson C, Bouchard C, Carlsson B, Dahlgren S, Jacobson P, Karason K, Karlsson J, Larsson B, Lindroos AK, Lönroth H, Näslund I, Olbers T, Stenlöf K, Torgerson J, Carlsson LM, Swedish Obese Subjects Study. 2009.** Effects of bariatric surgery on cancer incidence in obese patients in Sweden (Swedish Obese Subjects Study): a prospective, controlled intervention trial. *The Lancet. Oncology* **10**(7):653–662 DOI [10.1016/S1470-2045\(09\)70159-7](https://doi.org/10.1016/S1470-2045(09)70159-7).
- Sjöström L, Narbro K, Sjöström CD, Karason K, Larsson B, Wedel H, Lystig T, Sullivan M, Bouchard C, Carlsson B, Bengtsson C, Dahlgren S, Gummesson A, Jacobson P, Karlsson J, Lindroos AK, Lönroth H, Näslund I, Olbers T, Stenlöf K, Torgerson J, Agren G, Carlsson LM, Swedish Obese Subjects Study. 2007.** Effects of bariatric surgery on mortality in Swedish obese subjects. *The New England Journal of Medicine* **357**(8):741–752 DOI [10.1056/NEJMoa066254](https://doi.org/10.1056/NEJMoa066254).
- Song A, Xu M, Bi Y, Xu Y, Huang Y, Li M, Wang T, Wu Y, Liu Y, Li X, Chen Y, Wang W, Ning G. 2011.** Serum fetuin-A associates with type 2 diabetes and insulin resistance in Chinese adults. *PLOS ONE* **6**(4):e19228 DOI [10.1371/journal.pone.0019228](https://doi.org/10.1371/journal.pone.0019228).
- Stefan N, Fritsche A, Weikert C, Boeing H, Joost HG, Häring HU, Schulze MB. 2008.** Plasma fetuin-A levels and the risk of type 2 diabetes. *Diabetes* **57**(10):2762–2767 DOI [10.2337/db08-0538](https://doi.org/10.2337/db08-0538).
- Stefan N, Hennige AM, Staiger H, Machann J, Schick F, Kröber SM, Machicao F, Fritsche A, Häring HU. 2006.** Alpha2-Heremans-Schmid glycoprotein/fetuin-A is associated with insulin resistance and fat accumulation in the liver in humans. *Diabetes Care* **29**(4):853–857 DOI [10.2337/diacare.29.04.06.dc05-1938](https://doi.org/10.2337/diacare.29.04.06.dc05-1938).
- Stefan N, Sun Q, Fritsche A, Machann J, Schick F, Gerst F, Jeppesen C, Joost HG, Hu FB, Boeing H, Ullrich S, Häring HU, Schulze MB. 2014.** Impact of the adipokine adiponectin and the hepatokine fetuin-A on the development of type 2 diabetes: prospective cohort- and cross-sectional phenotyping studies. *PLOS ONE* **9**(3):e92238 DOI [10.1371/journal.pone.0092238](https://doi.org/10.1371/journal.pone.0092238).
- Sun Q, Cornelis MC, Manson JE, Hu FB. 2013.** Plasma levels of fetuin-A and hepatic enzymes and risk of type 2 diabetes in women in the U.S. *Diabetes* **62**(1):49–55 DOI [10.2337/db12-0372](https://doi.org/10.2337/db12-0372).

- Syu YF, Inui A, Chen CY. 2017. A perspective on metabolic surgery from a gastroenterologist. *Journal of Pharmacological Sciences* 133(2):61–64 DOI 10.1016/j.jphs.2017.01.001.
- Thakkestian A, Chailurkit L, Warodomwicit D, Ratanachaiwong W, Yamwong S, Chanprasertyothin S, Attia J, Sritara P, Ongphiphadhanakul B. 2014. Causal relationship between body mass index and fetuin-A level in the asian population: a bidirectional Mendelian randomization study. *Clinical Endocrinology* 81(2):197–203 DOI 10.1111/cen.12303.
- Ting CH, Syu YF, Chen LY, Lee FY, Lee SD, Lee WJ, Chen CY. 2016. Perspectives in interventional diabetology: Duodenal exclusion is promising for human type 2 diabetes mellitus remission. *Nutrition* 32(1):141–145 DOI 10.1016/j.nut.2015.07.006.
- Verras CG, Christou GA, Simos YV, Ayiomamitis GD, Melidonis AJ, Kiortsis DN. 2017. Serum fetuin-A levels are associated with serum triglycerides before and 6 months after bariatric surgery. *Hormones* 16(3):297–305 DOI 10.14310/horm.2002.1739.
- Yamagoe S, Akasaka T, Uchida T, Hachiya T, Okabe T, Yamakawa Y, Arai T, Mizuno S, Suzuki K. 1997. Expression of a neutrophil chemotactic protein LECT2 in human hepatocytes revealed by immunochemical studies using polyclonal and monoclonal antibodies to a recombinant LECT2. *Biochemical and Biophysical Research Communications* 237(1):116–120 DOI 10.1006/bbrc.1997.7095.
- Yamagoe S, Mizuno S, Suzuki K. 1998. Molecular cloning of human and bovine LECT2 having a neutrophil chemotactic activity and its specific expression in the liver. *Biochimica et Biophysica acta* 1396(1):105–113 DOI 10.1016/S0167-4781(97)00181-4.
- Yang PJ, Ser KH, Lin MT, Nien HC, Chen CN, Yang WS, Lee WJ. 2015. Diabetes associated markers after bariatric surgery: fetuin-A, but not matrix metalloproteinase-7, is reduced. *Obesity Surgery* 25(12):2328–2334 DOI 10.1007/s11695-015-1688-5.
- Yeh C, Huang HH, Chen SC, Chen TF, Ser KH, Chen CY. 2017. Comparison of consumption behavior and appetite sensations among patients with type 2 diabetes mellitus after bariatric surgery. *PeerJ* 5:e3090 DOI 10.7717/peerj.3090.
- Yoo HJ, Hwang SY, Choi JH, Lee HJ, Chung HS, Seo JA, Kim SG, Kim NH, Baik SH, Choi DS, Choi KM. 2017. Association of leukocyte cell-derived chemotaxin 2 (LECT2) with NAFLD, metabolic syndrome, and atherosclerosis. *PLOS ONE* 12(4):e0174717 DOI 10.1371/journal.pone.0174717.